From MarketBeat:

Payden & Rygel Investment Group recently purchased 5,300 shares of Amgen Inc. stock, worth $1,424,000. Roundview Capital LLC and Merit Financial Group LLC also increased their positions. Amgen stock opened at $325.33 with a market cap of $174.11 billion and has a 1 year low of $211.71 and high of $329.72.

Amgen announced a higher quarterly dividend of $2.25, up from $2.13, representing a yield of 2.77%. The firm has a dividend payout ratio of 60.55%. EVP Jonathan P. Graham sold 10,000 shares, total insider ownership is 0.57%. Stock analysts have given Amgen a “Moderate Buy” rating with a target price of $291.58.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics focusing on various areas including inflammation, oncology, and bone health. The company’s products include treatments for cancer, osteoporosis, and psoriasis. Analysts are weighing the potential for Amgen stock.

MarketBeat provides the latest on Amgen stock and reports on the company’s performance and activity. Top-rated analysts have identified five other stocks with more potential than Amgen, despite its “Moderate Buy” rating. Check out the five stocks that analysts are recommending over Amgen.



Read more: Payden & Rygel Investment Group Takes Position in Amgen Inc. (NASDAQ:AMGN)